New digital tools for remote, non-invasive and continuous diagnosis for chronic diabetic patients
Diabetes is the epidemic of this decade. Type 2 patients are estimated to affect 8.5% of the population, with a clear annual growth. Blood is currently considered the reference biofluid, but blood sampling is an invasive technique incompatible with the needs of diabetic patients.
Digital medicine together with artificial intelligence (AI) shows great potential for personalized management and treatment of chronic diabetic patients. iDiabetes seeks to develop new methods for diagnosis using sweat and saliva sensors.
iDiabetes’ ambition is to introduce new innovations at the component and system integration level which will make it easier to offer diabetes diagnosis and prognosis. There are three areas of innovation which will help iDiabetes achieve their objective:
Sigma Cognition’s role in this project is the development of cloud-based data management and deep learning to improve the control towards the personalized treatment of chronic diabetic patients.
The execution phase of iDiabetes began at the end of 2022 and is scheduled to be completed in the summer of 2025. The project is currently in the definition and identification of requirements stage.
As part of the iDIABETES project, several public databases on diabetes patients were analyzed and made available as part of Sigma AI’s “Open Datasets.”
The project is supported by the EU Next Generation funds through the State Research Agency (Agencia Estatal de Investigación) and is part of the Recovery, Transformation and Resilience Plan.
Bring us your toughest challenges and ambitious ideas — we’re excited to bring them to life.